MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Thermo Fisher Scientific Inc

Closed

SectorHealthcare

469.72 -3.98

Overview

Share price change

24h

Current

Min

468.06

Max

487.64

Key metrics

By Trading Economics

Income

194M

1.8B

Sales

795M

11B

P/E

Sector Avg

30.121

63.778

EPS

6.1

Dividend yield

0.35

Profit margin

16.007

Employees

125,000

EBITDA

377M

3B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+36.36% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.35%

2.39%

Next Earnings

23 kwi 2025

Next Dividend date

15 kwi 2025

Next Ex Dividend date

13 cze 2025

Market Stats

By TradingEconomics

Market Cap

-40B

189B

Previous open

473.7

Previous close

469.72

News Sentiment

By Acuity

33%

67%

106 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Thermo Fisher Scientific Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 lut 2025, 14:05 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Scientific to Acquire Solventum's Filtration Unit, Confirming WSJ Report

30 sty 2025, 11:43 UTC

Earnings

Thermo Fisher Scientific Profit, Revenue Rose in 4Q

23 paź 2024, 10:43 UTC

Earnings

Thermo Fisher Raises Floor of Earnings Target After Steady 3Q Sales

25 lut 2025, 14:09 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Strikes Deal for Solventum's Filtration Unit -- WSJ

25 lut 2025, 13:41 UTC

Acquisitions, Mergers, Takeovers

Solventum: Transaction Is Expected to Be Completed by End of 2025 >SOLV

25 lut 2025, 13:40 UTC

Acquisitions, Mergers, Takeovers

Solventum Expects Estimated $3.4 B in Net Proceeds >SOLV

25 lut 2025, 13:40 UTC

Acquisitions, Mergers, Takeovers

Solventum: Deal Strengthens Balance Sheet With Proceeds to Be Used Primarily for Debt Paydown >SOLV

25 lut 2025, 13:40 UTC

Acquisitions, Mergers, Takeovers

Solventum Expects Deal to Be Neutral to 2025 EPS >SOLV

25 lut 2025, 13:40 UTC

Acquisitions, Mergers, Takeovers

Solventum: Deal Accelerates Business Transformation and Sharpens Focus on Strategic Areas for Growth

25 lut 2025, 13:39 UTC

Acquisitions, Mergers, Takeovers

Solventum Announces Sale of Its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

25 lut 2025, 13:33 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher: Solventum Business Generated About $1 Billion Revenue in 2024 >TMO

25 lut 2025, 13:32 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher to Buy Solventum Purification, Filtration Business for About $4.1 Billion Cash >TMO SOLV

25 lut 2025, 13:32 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Scientific To Acquire Solventum's Purification And Filtration Business >TMO

24 lut 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Thermo Fisher Scientific Nears Deal for Solventum's Purification and Filtration Business, Sources Say -- WSJ

24 lut 2025, 23:03 UTC

Top News
Acquisitions, Mergers, Takeovers

Thermo Fisher Nears Deal for Solventum Filtration Unit -- WSJ

24 lut 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Deal Could be Announced This Week, Sources Say -- WSJ

24 lut 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Transaction Could Value Solventum Filtration Business Between $3.5B to $4B, Sources Say -- WSJ

30 sty 2025, 11:06 UTC

Earnings

Thermo Fisher: In a Great Position to Deliver Excellent Performance in 2025 >TMO

30 sty 2025, 11:05 UTC

Earnings

Thermo Fisher: Will Provide 2025 Fincl Guidance During Earnings Conference Call Thursday Morning >TMO

30 sty 2025, 11:00 UTC

Earnings

Thermo Fisher 4Q Rev $11.4B >TMO

30 sty 2025, 11:00 UTC

Earnings

Thermo Fisher 4Q EPS $4.78 >TMO

30 sty 2025, 11:00 UTC

Earnings

Thermo Fisher 4Q Core Organic Revenue Up 5% >TMO

30 sty 2025, 11:00 UTC

Earnings

Thermo Fisher 4Q Net $1.83B >TMO

30 sty 2025, 11:00 UTC

Earnings

Thermo Fisher 4Q Adj EPS $6.10 >TMO

16 gru 2024, 22:03 UTC

Top News

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

23 paź 2024, 10:02 UTC

Earnings

Thermo Fisher Had Seen 2024 Adjusted EPS $21.29-$22.07 >TMO

23 paź 2024, 10:02 UTC

Earnings

Thermo Fisher Backs 2024 View of Rev $42.4B-$43.3B >TMO

23 paź 2024, 10:00 UTC

Earnings

Thermo Fisher 3Q Core Organic Revenue 0% >TMO

23 paź 2024, 10:00 UTC

Earnings

Thermo Fisher 3Q EPS $4.25 >TMO

23 paź 2024, 10:00 UTC

Earnings

Thermo Fisher 3Q Adj EPS $5.28 >TMO

Peer Comparison

Price change

Thermo Fisher Scientific Inc Forecast

Price Target

By TipRanks

36.36% upside

12 Months Forecast

Average 666.88 USD  36.36%

High 715 USD

Low 570 USD

Based on 17 Wall Street analysts offering 12 month price targets forThermo Fisher Scientific Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

14

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

481.21 / 513.42Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

106 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar